RemeGen (688331.SH/09995.HK) announced that the 48-week open-label extension (OLE) data from China Phase III clinical study of telitacicept (RC18, brand name: 泰爱®, a BLyS/APRIL dual-target fusion ...

In the second quarter of 2025, U.S. equity markets rebounded notably following a challenging first quarter. Read more here.

The Texas A&M Student Government Association sent a letter of support for President Mark A. Welsh III to Chancellor Glenn Hegar and the board of regents on Wednesday.